JP2018529760A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529760A5
JP2018529760A5 JP2018527836A JP2018527836A JP2018529760A5 JP 2018529760 A5 JP2018529760 A5 JP 2018529760A5 JP 2018527836 A JP2018527836 A JP 2018527836A JP 2018527836 A JP2018527836 A JP 2018527836A JP 2018529760 A5 JP2018529760 A5 JP 2018529760A5
Authority
JP
Japan
Prior art keywords
fviii
coagulation factor
modified
protein
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
JP2018527836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529760A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/046264 external-priority patent/WO2017027545A1/en
Publication of JP2018529760A publication Critical patent/JP2018529760A/ja
Publication of JP2018529760A5 publication Critical patent/JP2018529760A5/ja
Revoked legal-status Critical Current

Links

JP2018527836A 2015-08-12 2016-08-10 長半減期凝固複合体と関連する方法及び組成物 Revoked JP2018529760A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562203973P 2015-08-12 2015-08-12
US62/203,973 2015-08-12
PCT/US2016/046264 WO2017027545A1 (en) 2015-08-12 2016-08-10 Methods and compositions related to long half-life coagulation complexes

Publications (2)

Publication Number Publication Date
JP2018529760A JP2018529760A (ja) 2018-10-11
JP2018529760A5 true JP2018529760A5 (enExample) 2020-12-03

Family

ID=57983769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018527836A Revoked JP2018529760A (ja) 2015-08-12 2016-08-10 長半減期凝固複合体と関連する方法及び組成物

Country Status (10)

Country Link
US (2) US10596232B2 (enExample)
EP (1) EP3334452A4 (enExample)
JP (1) JP2018529760A (enExample)
KR (1) KR20180031775A (enExample)
CN (1) CN107921103A (enExample)
AU (1) AU2016304842A1 (enExample)
BR (1) BR112018002838A2 (enExample)
CA (1) CA2994971A1 (enExample)
IL (1) IL257406A (enExample)
WO (1) WO2017027545A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061281A1 (en) * 2018-09-19 2020-03-26 Cell Machines, Inc. Methods and compositions related to improved factor viii long half-life coagulation complexes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
ES2353084T3 (es) * 2006-04-07 2011-02-25 Novo Nordisk Health Care Ag Complejo covalente de factor vii y factor tisular.
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP2467166A2 (en) 2009-08-20 2012-06-27 CSL Behring GmbH Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
WO2011101284A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii fusion protein
US9234192B2 (en) * 2010-02-16 2016-01-12 Novo Nordisk A/S Conjugated proteins
ES2800983T3 (es) * 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
ES2770501T3 (es) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
FR3007860A1 (fr) * 2013-06-27 2015-01-02 France Telecom Procede d'interaction entre un objet numerique, representatif d'au moins un objet reel ou virtuel localise dans un perimetre geographique distant, et un dispositif de pointage local
HK1223303A1 (zh) * 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 凝血酶可裂解连接子

Similar Documents

Publication Publication Date Title
JP6527918B2 (ja) 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
EP3243833B1 (en) Site-directed modification of fviii
JP2023134851A (ja) 第ｖｉｉｉ因子キメラおよびハイブリッドポリペプチドならびにその使用法
KR20110017420A (ko) 폰 빌레브란트 질환의 치료를 위한 ｆｖｉｉｉ 뮤테인
US20200289624A1 (en) Methods and compositions related to long half-life coagulation complexes
US20220118063A1 (en) Methods and compositions related to improved factor viii long half-life coagulation complexes
AU2016203693B2 (en) Site-directed modification of FVIII